Medical Attention for Nephropathy

The percentage of patients 18-75 years of age with diabetes (type 1 and type 2) who received a nephropathy screening or monitoring test or had evidence of nephropathy during the measurement year.

Date Reviewed: November 4, 2018

Measure Info

MIPS 119 NQF 0062 CMS 119 NQF Endorsed
Measure Type
Measure Steward
National Committee for Quality Assurance
Clinical Topic Area

Care Setting
Data Source
Electronic Health Records
Paper Medical Records

ACP supports MIPS measure ID# 119 (NQF ID# 0062): “Diabetes: Medical Attention for Nephropathy” because the opportunity for improvement is well documented, developers cite 2018 clinical recommendations of the American Diabetes Association on “Standards of Medical Care in Diabetes” to form the basis of the measure, the numerator and denominator are well defined, the denominator includes well specified and clinically appropriate exceptions to eligibility for the measure, and measurement is repeatable and precise.